Yhasmine Delles Oliveira Garcia

Yhasmine Delles Oliveira Garcia

Auto-generated profile, based on publicly available information

Yhasmine Delles Oliveira Garcia

Federal University of Ceará Walter Cantídio Hospital, Fortaleza, Brasil

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2024 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
FDFernando Barroso Duarte
Fernando Barroso Duarte
YGYhasmine Delles Oliveira Garcia
Yhasmine Delles Oliveira Garcia
NHNelson Hamerschlak
Nelson Hamerschlak
VFVaneuza Araújo Moreira Funke
Vaneuza Araújo Moreira Funke
MMMaria Claudia Rodrigues Moreira
Maria Claudia Rodrigues Moreira
MFMary E. Flowers
Mary E. Flowers
This study analyzed recent changes in the utilization of allogeneic HCT for treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative diseases (MPD) and the survival of HCT recipients ≥60 years of age in Brazil. This retrospective registry study included patients who received a first allogeneic HCT from any donor between 2012 and 2023. Of the 6657 patients, 444 (7%) were 60 years of age or older who received grafts from HLA-matched related (42%) or unrelated (20%) donors or HLA-haploidentical donors (32%). The proportion of HCT recipients 60 years of age or older increased gradually from 3.2% in 2012 to 16% in 2023 mostly due to the increased use of HLA-haploidentical donors since 2018. Overall survival (OS) at day 100 was 77%, and estimated OS at 12 months was 53% (95% CI, 48-58). OS at 12-months was higher for transplants during 2015-2017 (58%) and 2018-2020 (68%) compared to 2012-2014 (45%), but it did not differ for those during 2021-2023 (49%). Mortality with HLA-haploidentical donors (HR 2.35; 95%CI; 1.65-3.34 [p <0.001]) and cord blood donors (HR 4.68; 95%CI,1.29-16.9 [p= 0.01]) was higher than with HLA-matched related donors. Mortality was lower for transplants during the 2015-2020 period (HR 0.57; 95%CI, 0.34-0.96 [0.037]) than for those during 2012-2014.This study revealed a gradual increase in the use of allogeneic HCT in individuals aged 60 years and older in Brazil. While use of haploidentical donor has increased worldwide, its association with increased mortality in elderly population deserves caution.

1 July 2019 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
DODeivide de Sousa Oliveira
Deivide de Sousa Oliveira
JMJuliene Lima Mesquita
Juliene Lima Mesquita
YGYhasmine Delles Oliveira Garcia
Yhasmine Delles Oliveira Garcia
YRYensy Mariana Zelaya Rosales
Yensy Mariana Zelaya Rosales
RLRomélia Pinheiro Gonçalves Lemes
Romélia Pinheiro Gonçalves Lemes
FDFernando Barroso Duarte
Fernando Barroso Duarte

26 June 2025 in European Journal of Haematology
Verified
Journal Article
Open access
FDFernando Barroso Duarte
Fernando Barroso Duarte
YGYhasmine Delles Oliveira Garcia
Yhasmine Delles Oliveira Garcia
VFVaneuza ARAUJO MOREIRA Funke
Vaneuza ARAUJO MOREIRA Funke
AJAnderson João
Anderson João
NHNelson Hamerschlak
Nelson Hamerschlak
VCVergílio Antônio Rensi Colturato
Vergílio Antônio Rensi Colturato
This retrospective multicenter study aimed to compare outcomes and evaluate risks associated with allogeneic hematopoietic cell transplantation (allo‐HCT) in myelodysplastic syndrome patients aged ≥ 65 versus < 65 years in Latin America, across 38 transplant centers (1988–2023). Of the 441 patients, 70 (16%) were ≥ 65 years (median age 68 ± 3.7). At 5 years, overall survival (OS) was 49.3% in patients ≥ 65 vs. 56.7% in those < 65 (p = 0.49), and progression‐free survival (PFS) was 48.4% vs. 56.2% (p = 0.40). The cumulative incidence of relapse was 13.6%, and non‐relapse mortality (NRM) 33.8%. After propensity score matching, no significant differences were observed between the age groups in OS (HR = 1.16; 95% CI: 0.76–1.77; p = 0.488), NRM (HR = 1.03; 95% CI: 0.64–1.67; p = 0.90) or PFS (HR = 1.20; 95% CI: 0.779–1.83; p = 0.40). PFS in patients ≥ 65 years was associated with high‐risk IPSS‐R stratification (p = 0.0056). The age group ≥ 65 years conferred higher risk of relapse compared to patients aged < 65 years (HR = 2.77; 95% CI: 1.07–7.15; p = 0.035). In patients ≥ 65 years, prevalence risk was associated to male sex, reduced‐intensity conditioning, mobilized blood cells, and prior treatment, while in those < 65 years, to complications and chronic GVHD (p < 0.05). HCT is feasible in elderly patients. However, age may influence disease progression in very high‐risk elderly patients and risk of relapse after transplantation.

24 April 2026 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
FDFernando Barroso Duarte
Fernando Barroso Duarte
YGYhasmine Delles Oliveira Garcia
Yhasmine Delles Oliveira Garcia
VRVanderson Rocha
Vanderson Rocha
VFVaneuza ARAUJO MOREIRA Funke
Vaneuza ARAUJO MOREIRA Funke
MMMaria Claudia Rodrigues Moreira
Maria Claudia Rodrigues Moreira
NHNelson Hamerschlak
Nelson Hamerschlak

1 May 2020 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
JMJuliene Lima Mesquita
Juliene Lima Mesquita
YRYensy Mariana Zelaya Rosales
Yensy Mariana Zelaya Rosales
YGYhasmine Delles Oliveira Garcia
Yhasmine Delles Oliveira Garcia
FFFrancisco Dario Rocha Filho
Francisco Dario Rocha Filho
BABeatriz Stela Gomes de Sousa Pitombeira Araujo
Beatriz Stela Gomes de Sousa Pitombeira Araujo
FDFernando Barroso Duarte
Fernando Barroso Duarte
Splenic marginal zone B-cell lymphoma is a rare type of non-Hodgkin B-cell lymphoma, without preference for sex, which affects individuals mainly over 50 years. In many cases, the disease is asymptomatic, with absent splenomegaly and lymphadenomegaly. The changes in the peripheral blood, when present, are lymphocytosis, anemia, and thrombocytopenia; cytopenias are mostly due to hypersplenism. The presence of B symptoms and increased LDH is rare1 , 2 . The immunophenotype pattern is characterized by pan-B cell expression with positive CD19, CD20, CD22, CD79a, IgM, and IgD. CD5 is found only in 15%, and CD23 in 30% of cases. It presents as the most common cytogenetic alteration the heterogeneous expressions of chromosome 7, the (9:14) (p13: q32), which overlaps the IgH and PAX-53 genes. The marrow infiltration patterns are highly variable and consist of nodular, paratrabecular, and interstitial4 , 5 . The finding of the intrasinusoidal pattern is more easily observed by CD20 or CD34 immunohistochemistry. Spleen histology shows micronodular infiltration of white pulp with biphasic pattern and a variable degree of red pulp involvement. Differential diagnosis should be made with other chronic B7 cell lymphoproliferative diseases5 .

12 May 2024 in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Verified
Journal Article
Open access
PDF file
FDFernando Barroso Duarte
Fernando Barroso Duarte
YGYhasmine Delles Oliveira Garcia Garcia
Yhasmine Delles Oliveira Garcia Garcia
RPRafaela Cristiny Remigio Pitombeira
Rafaela Cristiny Remigio Pitombeira
MBMissielle Duarte Cordeiro Barroso
Missielle Duarte Cordeiro Barroso
RARafael Da Nobrega de Alencar
Rafael Da Nobrega de Alencar
MPMaria Da Silva Pitombeira
Maria Da Silva Pitombeira
Discutir a elegibilidade precocemente no Transplante de Medula Óssea (TMO) reduz o tempo de espera, a busca de doadores e acelera o acesso aos cuidados pré-transplante. O estudo descreve a otimização do acesso ao TMO por meio de um ambulatório para avaliação de pacientes pré-transplante. Estudo retrospectivo, 2021-2023 no Hospital Universitário Walter Cantídio. Dados analisados ​​no SPSS. Mostra 226 transplantes de 3.646 consultas. A clínica encaminhou 45 pacientes, contribuindo com 19,1%, 11,7% e 22,1% dos transplantes em 2021, 2022 e 2023, respectivamente, em comparação com <5% nos anos anteriores. Este aumento destaca a importância do acesso rápido aos cuidados pré-transplante, resultando num maior número de pacientes elegíveis para transplante.